   
  
IP/C/R/TC/WHO/4  
 
16 October 2023  
(23-6950)  Page: 1/17 
Council for Trade -Related Aspects  of 
Intellectual Property Rights  Original: English   
 
TECHNICAL COOPERATION ACTIVITIES: INFORMATION FROM  
OTHER INTERGOVERNMENTAL ORGANIZATIONS  
WORLD HEALTH ORGANIZATION (WHO)  
At its meeting of  14-15 June 2023, the Council for TRIPS agreed to invite intergovernmental 
organization observers to the Council to update the information on their technical and financial 
cooperation programmes relating to the implementation of the TRIPS Agreement.  
 
The present document reproduces the information which has been received from the World Health  
Organization (WHO)  by means of a communication dated  10 October 2023 . 
 
_______________  
 
 
1  INTRODUCTION  
1.  This communication summarizes the technical cooperation activities of the World Health 
Organization (WHO) in the area of public health, innovation and intellectual property that have taken 
place since the last report in October 2022 (document IP/C/R/TC/WHO/3). The overall objective of 
WHO's technical cooperation is to strengthen the capacity of developing countries in the areas of 
health i nnovation, timely access to medicines and management of intellectual property in a manner 
that maximizes public health.  
2.  WHO's technical cooperation is based on its mandate derived from the Global Strategy and Plan 
of Action on Public Health, Innovation and  Intellectual Property (GSPA -PHI) as well as relevant 
resolutions and decisions of the World Health Assembly, including WHA72.8 on "Improving the 
transparency of markets for medicines, vaccines, and other health products "1, WHA73.1 on the 
"COVID -19 respon se,"2 WHA74.6 on "Strengthening local production of medicines and other health 
technologies to improve access "3 and WHA75.14 on the extension of the time frame of the "Global 
Strategy and Plan of Action on Public Health, Innovation and Intellectual Property " from 2022 to 
2030.4 
3.  In resolution WHA74.6, the Seventy -fourth World Health Assembly emphasized the need to 
improve access to quality, safe, effective and affordable medicines and other health technologies, 
inter alia, through cooper ation with, support to and development of voluntary patent pools and other 
voluntary initiatives, such as the WHO COVID -19 Technology Access Pool (C -TAP). WHA74.6, inter 
alia, requested the WHO Director -General to continue to provide technical support, as appropriate, 
upon request, in collaboration with other competent international organizations, like the World 
Intellectual Property Organization (WIPO) and the World Trade Organization (WTO), including to 
policy processes and to countries that intend to mak e use of the provisions contained in the 
TRIPS  Agreement, including the flexibilities affirmed by the Doha Declaration on the TRIPS 
Agreement and Public Health in order to promote access to pharmaceutical products .5 
 
1 https://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_R8 -en.pdf . 
2 https://apps.who.int/gb/ebwha/pdf_files/WHA73/A73_R1 -en.pdf . 
3 https://apps.who.int/gb/ebwha/pdf_files/WHA74/A74_R6 -en.pdf . 
4 https://apps.who.int/gb/ebwha/pdf_files/WHA75/A75_R14 -en.pdf . 
5 https://apps.who.int/gb/ebwha/pdf_files/WHA74/A74_R6 -en.pdf . IP/C/R/TC/WHO/4  
 
- 2 - 
 
  4.  WHO, through its Headquarters, Regional  and Country Offices collaborates closely with relevant 
international organizations on topics related to the interface between public health, innovation, 
intellectual property and trade. WHO has requested full support and collaboration from WIPO, WTO 
and o ther international organizations to ensure efficient and effective implementation of certain 
prioritized actions of the GSPA -PHI overall programme review panel. Activities focus on technical 
guidance, transfer of technology, local manufacturing, capacity -building and training, and direct 
technical assistance to countries. WHO, WIPO and WTO worked in close collaboration to respond to 
the challenges posed by the COVID -19 pandemic in relation to the integrated health, trade and IP 
policy framework, including e quitable access to COVID -19 health technologies, such as medicines, 
vaccines, medical devices, and diagnostics.  
5.  Following the WHO Director -General 's declaration that COVID -19 no longer constitutes a public 
health emergency of international concern (PHEIC),  the three organizations have continued to work 
together to ensure preparedness and effective response to future pandemics .6 
2  AN INTEGRATED HEALTH, TRADE AND INTELLECTUAL PROPERTY APPROACH TO 
RESPOND TO THE COVID -19 PANDEMIC  
6.  On 14 July 2023, WHO, WIPO and WTO launched the second update of the extract "Integrated 
health, trade and IP approach to respond to the COVID -19 pandemic ".7 This extract maps the 
challenges posed by the COVID -19 in relation to the integrated health, trad e and intellectual property 
framework set out in the second edition of the Trilateral Study on "Promoting Access to Medical 
Technologies and Innovation ".8 The update contains developments up until 17 May 2023, and covers 
topics including the impact of COV ID-19 on health systems and responses at the global level, policy 
challenges, meeting the demand for health technologies and medical services, international trade, 
intellectual property aspects, international initiatives to support research and development  and 
equitable access, regulatory responses, transparency and mapping the way forward. The update 
also highlights IP -related measures implemented by both developed and developing countries to 
facilitate access to COVID -19 health technologies during the pan demic.  
3  INTENSIFIED COOPERATION IN SUPPORT OF ACCESS TO MEDICAL TECHNOLOGIES 
WORLDWIDE TO TACKLE THE COVID -19 PANDEMIC AND PREPARE FOR FUTURE 
PANDEMICS  
7.  The Directors -General of the WHO, WIPO and WTO agreed to organize practical capacity -building 
workshops a t the technical level to enhance the flow of updated information on current developments 
in the pandemic and responses to achieve equitable access to COVID -19 health technologies .9 The 
third in the series of workshops titled "WHO-WIPO -WTO Workshop on Inno vation and Access to 
diagnostics for COVID -19 and beyond " was held on 28 October 2022. The workshop, held virtually, 
was focused on diagnostics – specifically, in vitro diagnostics – and there were discussions on 
challenges, opportunities and the way forwa rd to secure innovation and access to diagnostics. This 
was aimed at, among others, strengthening capacity of policymakers and experts in member 
governments to assess medical devices and diagnostics therapeutic technologies in response to 
COVID -19.10 
8.  On 16  December 2022, WHO, WIPO and WTO held a joint technical symposium on "COVID -19 
Pandemic: Response, Preparedness, Resilience ". The Symposium was the ninth in a series of joint 
technical symposia convened by the three organizations. The objective of the Sym posium was to 
examine key challenges of the COVID -19 pandemic experienced within the frameworks of health, 
 
6 https://www.who.int/news/item/05 -05-2023-statement -on-the-fifteenth -meeting -of-the-international -
health -regulations -(2005) -emergency -committee -regarding -the-coronavirus -disease -(covid -19)-pandemic . 
7 https://www.who.int/publications/m/item/an -integrated -health--trade -andip -approach -to-respond -to-
thecovid -19-pandemic ---second -update --may-2023. 
8 https://www.who -wipo-wto-trilateral.org/files/wipo_pub_628_2020__en.pdf . 
9 https://www.wipo.int/pressroom/en/articles/2021/article_0006.html . 
10 https://www.who.int/news -room/events/detail/2022/10/28/default -calendar/who -wipo-wto-
workshop ---innovation -and-access -to-diagnostics -for-covid-19-and-
beyond#:~:text=The%20World%20Health%20Organization%20(WHO,Geneva%20time)%20in%20virtual%20
format . IP/C/R/TC/WHO/4  
 
- 3 - 
 
  trade and intellectual property (IP) and to discuss the way forward to build resilience to be better 
prepared for future pandemics. This event was he ld in hybrid format at the WIPO headquarters .11 
9.  On 27 June, 2023, WHO, WIPO and WTO jointly organized a webinar on "Technology Transfer 
from the Perspectives of Practitioners ". This practical capacity -building webinar was the fourth in the 
series of trilat eral workshops and it drew from the experience and perspectives of technology transfer 
practitioners working on the ground. The purpose of the webinar was to strengthen the capacity of 
policymakers and experts to achieve equitable access to COVID -19 health  technologies and to be 
better prepared for future pandemics. The event was hosted by the WTO .12 
10.  The three organizations continue to intensify cooperation through regular coordination meetings 
at Technical, Directors, and ADG/DDGs levels. Additionally, on 12 September 2023, the 
Directors -General of WHO, WIPO and WTO met in Geneva to agree on future directions for trilateral 
cooperation. This was their third meeting since the onset of the COVID -19 pandemic. They agreed 
to shift the focus of trilateral cooperation from the response to the COVID -19 pandemic to increasing 
and broadening support for more effective and sustainable use of flexibilities in the WTO Agreement 
on Trade -Related Aspects of Intellectual Property Rights (TRIPS) to increase  access to health 
technologies and to be better prepared for future pandemics. To mirror this broader focus of trilateral 
cooperation, and to respond to members ' evolving needs, the Directors -General agreed to expand 
the use of the WHO -WIPO -WTO COVID -19 Te chnical Assistance Platform beyond COVID -19. Noting 
the multiple crises caused by climate change, environmental degradation and biodiversity loss and 
their impact on human health, they also agreed to make climate change and human health the topic 
of the ne xt session in the series of high -level trilateral policy symposia .13 
4  ACCESS ORIENTED LICENSING AND COVID -19 TECHNOLOGY ACCESS POOL (C -TAP)  
11.  Since its creation in May 2020, the WHO COVID -19 Technology Access Pool (C -TAP) has 
prioritized engagement with techn ology holders to encourage sharing of intellectual property, know -
how or data to promote global equitable access to COVID -19 vaccines, therapeutics, diagnostics or 
other medical devices. In July 2023, under the auspices of C -TAP, the Medicines Patent Pool (MPP) 
signed a worldwide license with Medigen Vaccine Biologics Corp. for a COVID -19 vaccine based on 
the COVID -19 spike protein sequence that it licensed from the US National Institutes of Health 
(NIH) .14 More than three million doses of the vaccine have been administered across seven 
countries .15 This is the first transparent, global, non -exclusive license for a COVID -19 vaccine and 
the first health technology developed by a private company and included in C -TAP.  
12.  In July 2023, under the auspices of C -TAP, the MPP signed a worldwide license with the Spanish 
National Research Council (CSIC) for a COVID -19 vaccine consisting of a Modified Vaccinia Virus 
Ankara (MVA) vector expressing a full -length prefusion -stabilized SARS -CoV-2 spike protein and 
called MVA -CoV2-S(3P) (the CSIC COVID -19 Vaccine) .16  This is the second technology developed 
by CSIC and included in C -TAP.  
13.  In July 2023, under the auspices of C -TAP, the MPP signed a worldwide license with the University 
of Chile for a system for quantification of neutralizing antibodies (NAbs) against SARS -CoV-2. This 
diagnostic can be used in facilities using heightened control measures similar to Biosafety Level 2 
(BSL-2) laboratories .17 The agreement covers transfer of all know -how, protocols a nd biological 
materials needed to manufacture the diagnostic test.  
14.  C-TAP launched the WHO Technology Access Pool Database in August 2023 to provide 
wide-ranging information on selected therapeutics, diagnostics, vaccines and other health products 
 
11 https://www.wipo. int/meetings/en/details.jsp?meeting_id=72248 . 
12 https://cdn.who.int/media/docs/default -source/essential -medicines/intellectual -property/trilateral -
webinar -on-technology -transfer -programme -27june2023.pdf?sfvrsn=cec74276_1 . 
13 https://www.wto.org/english/news_e/news23_e/igo_13sep23_e.htm . 
14 https://www.who.int/initiatives/covid -19-technology -access -pool/medigen -license -to-c-tap. 
15 https://www.who.int/news/item/29 -08-2023-who-initiative -signs-new-licensing -agreements -on-
covid-19-technologies . 
16 https://www.who.int/initiatives/covid -19-technology -access -pool/csic -license -to-c-tap. 
17 https://www.who.int/initiatives/covid -19-technology -access -pool/university -of-chile-license -to-c-tap. IP/C/R/TC/WHO/4  
 
- 4 - 
 
  to tackle  COVID -19 and other endemic diseases .18 This publicly available database includes inter 
alia, information on clinical trials, patents and licensing, manufacturers, and regulatory status of key 
health products for informed decision -making. In line with the WHO transparency resolution, it 
enhances WHO 's work on promoting transparency of data across the value chain for health products 
towards achieving universal health coverage .19 Also, it supports existing efforts to determine the 
patent status of health products, in line with the GSPA -PHI.  
15.  To secure voluntary transfer of additional health technologies, C -TAP has been collaborating with 
the University of Cape Town, a public research university based in Cape Town, South Africa, and the 
Sree Chitra T irunal Institute for Medical Sciences and Technology (SCTIMST), an Institution of 
National Importance under the Department of Science and Technology in India. This is to ensure 
cooperation and understanding for the efficient transfer of essential health te chnologies created by 
these reputed research institutions. The transfer of technologies might take the form of intellectual 
property, knowledge, and/or data and may include the provision of training, capacity building, 
technical and logistical advice, and support.  
16.  WHO launched a study on "Strategies to facilitate sharing of technology and knowledge ". This 
study is aimed at promoting engagement of technology holders with C -TAP to share essential health 
technologies for global equitable access. The WHO secret ariat administered a questionnaire for 
member States to identify legislation, regulations, guidelines and procedures that can be amended 
or introduced to encourage sharing of health technologies. The study summarizes responses from 
member States and analyz es possible measures that may be implemented at the country level to 
encourage participation of technology holders in C -TAP. The discussion contained in the study is 
intended to inform all actors involved in the process of introducing or amending legislati ons, 
regulations, guidelines, and procedures to implement incentives for voluntary transfer of critical 
health technologies to reduce the dire effects of health emergencies globally.  
17.  A review of C -TAP was undertaken by WHO to assess the successes, challeng es, and possible 
areas for improvement of the mechanism based on experience to date.  The review included C -TAP's 
mission and scope, governance structure and operating model, stakeholder engagement, and 
performance – both overall and across the technology d evelopment – licensing – technology 
transfer/scale -up and access dimensions. The review was also designed to inform the possible 
post-pandemic role of an evolved C -TAP model in addressing future pandemics and other public 
health issues within the broader h ealth products ecosystem with a view to promoting synergies and 
increasing collective impact.   WHO is preparing to share findings of the review of C -TAP and a 
proposed model for an evolved technology access pool. Stakeholders will have an opportunity to 
provide comments on a concept paper including the process and timelines for its implementation.  
18.  On 11 April 2023, WHO together with Unitaid and with the support of Medicines Law & Policy 
jointly published a briefing document for member States on "Improving a ccess to novel COVID -19 
treatments ".20 The document explains some of the legal instruments that WHO member States can 
use to promote public health and access to COVID 19 therapeutics in the framework of their 
multilateral trade obligations and rights, and according to their national legislation and level of 
development.   It is intended to support countries dealing with challenges at the intersection of public 
health and intellectual property, to increase access to novel COVID -19 therapeutics and to facilita te 
alternative and more affordable sourcing of such treatments, where possible. Member States should 
use all tools available to them, including voluntary licensing, to overcome intellectual property 
barriers. Countries that are not covered by voluntary lic enses are encouraged to use to the full 
flexibilities under the Agreement on Trade -Related Aspects of Intellectual Property Rights 
(TRIPS  Agreement) and the Doha Declaration on the TRIPS Agreement and Public Health.  
5  THE MRNA VACCINE TECHNOLOGY TRANSFER HUB  
19.  Launched in July 2021, the mRNA vaccine technology transfer hub was established by WHO 
together with partners and a South African consortium to build capacity in low - and middle -income 
countries to produce mRNA vaccines, thus promoting equitable access in  under -served regions.21 
 
18 https://www.who.int/news/item/29 -08-2023-who-initiative -signs-new-licensing -agreements -on-
covid-19-technologies  ; https://tap -database.who.int . 
19 https://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_R8 -en.pdf . 
20 https://www.who.int/publications/m/item/improving -accessto -novel -covid-19treatments . 
21 https://www.who.int/initiatives/the -mrna-vaccine -technology -transfer -hub. IP/C/R/TC/WHO/4  
 
- 5 - 
 
  Afrigen  Biologics and Vaccines – a member of the consortium mandated to establish mRNA vaccine 
production technology – has successfully established a COVID -19 vaccine manufacturing process at 
laboratory scale.22 The first batches of the COVID -19 vaccine candidate , AfriVac 2121, have already 
been produced. The vaccine is currently being developed to a level suitable for phase 1 and 2 clinical 
trials. In April 2023, WHO and partners inaugurated a mRNA technology hub facility at Afrigen for 
the next phase of the mRNA  vaccine development. In a parallel process, Afrigen continues to carry 
out training and technology transfer to the network partners.  
20.  In May 2023, WHO and the Republic of Korea signed a Memorandum of Understanding to 
establish a global training hub in biom anufacturing.23 This global training centre will serve all low - 
and middle -income countries (LMICs) to produce biologicals, such as vaccines, insulin, monoclonal 
antibodies, and cancer medicines. This initiative will contribute to building a skilled workfo rce with 
unique competencies required in bioproduction. The global bio -manufacturing training hub will 
complement the trainings delivered by the mRNA vaccine technology transfer hub in South Africa.  
6  ACCESS TO COVID -19 TOOLS ACCELERATOR (ACT -A) 
21.  In July 2022 , the ACT -A Facilitation Council commissioned an independent, external evaluation 
of ACT -A with the objective of learning from ACT -A experiences and to identify key lessons learnt 
for future pandemic preparedness and response.24 The evaluation was also aim ed at providing 
learnings for institutional solutions to enhance global equitable access to medical countermeasures 
(MCMs) in the future. The evaluation was carried out between 11 July 2022 and 10 October 2022. 
Inputs were gathered from countries, regional  organizations, ACT -A agencies, civil society 
organizations, academia, and the private sector.25 In addition to key findings, the evaluation 
highlighted lessons learnt from ACT -A's experiences as the need for: increased research and 
development coordinatio n, a contingent funding platform for medical countermeasures, improved 
global functions, building regional manufacturing capacity and health systems strengthening.  
22.  In October 2022, ACT -A introduced changes to its setup and ways of working as the COVID -19 
pandemic waned.26 The transition was aimed at supporting countries with long -term COVID -19 
control, specifically by ensuring that countries have sustained access to the vaccines, tests, and 
treatments needed to manage the SARS -CoV-2 virus. Among others, the  ACT-A Facilitation Council 
went into stand -by mode and its key functions are being performed by a new ACT -A Tracking and 
Monitoring Task Force. The transition plan set out three core areas for the next phase of ACT -A's 
work, namely, focusing on R&D and ma rket shaping activities for a new pipeline of COVID -19 tools; 
securing longer -term institutional arrangements for sustained access to COVID -19 tools; and 
concentrating delivery work on new product introduction and the protection of priority populations, 
in support of national and international coverage targets.27 In May 2023, ACT -A reported progress 
made by its partner agencies in implementing these transition objectives.28 
7  MEDICAL COUNTERMEASURES PLATFORM FOR PANDEMICS  
23.  In February 2023, WHO convened a desi gn and consultation process on a new medical 
countermeasures platform for pandemics to build on experiences and learnings from ACT -A, the 
Pandemic Influenza Preparedness Framework (PIP) and other relevant inter -agency initiatives 
 
22 https: //www.who.int/news/item/20 -04-2023-mrna-technology -transfer -programme -moves -to-the-
next-phase -of-its-development . 
23 https://www.who.int/news/item/26 -05-2023-WHO-and-Republic -of-Korea -sign-landmark -agreement -
to-boost -biomanufacturing -
capac ity#:~:text=WHO%20and%20the%20Republic%20of,monoclonal%20antibodies%2C%20and%20cancer
%20medicines . . 
24 https://www.who.int/publications/m/item/external -evaluation -of-the-access -to-covid-19-tools-
accelerator -(act-a) . 
25 https://www.who.int/publications/m/item/external -evaluation -of-the-access -to-covid-19-tools-
accelerator -(act-a) . 
26 https://www.who.int/publications/m/item/act -accelerator -transition -plan-(1-oct-2022-to-31-mar-
2023) . 
27 https://www.who.int/publications/m/item/act -accelerator -transition -plan-(1-oct-2022-to-31-mar-
2023) . 
28 https://www.who.int/publications/m/item/act -accelerator -transition -report . IP/C/R/TC/WHO/4  
 
- 6 - 
 
  focused on epidemic -prone diseases.29 An important goal of this process is to help achieve 
convergence of the many parallel discussions underway on enhancing access to countermeasures, 
with the aim of ensuring that all these efforts are working for a common purpose. The consultatio n 
process will encompass three key issues that are essential to the design of a future medical 
countermeasures platform: governance, operating model, and surge financing.  
24.  Upon completion of an initial prototyping phase, a High -Level Consultative Group – made up of 
high-level officials and representatives from countries, international organizations and agencies, 
industry, regional entities, and civil society – will take forward the consultations with a view towards 
reaching convergence on a new 'working ' platform.30 
 
 
29 https://cdn.who.int/media/docs/default -source/documents/emergencies/countermeasures -
platform_w ho-consultative -process ---concept.pdf?sfvrsn=7f23de34_2 . 
30 https://www.who.int/news -room/articles -detail/who -design -and-consultation -process -on-a-new-
medical -counter measures -platform -for-pandemics .  
  IP/C/R/TC/WHO/4  
 
- 7 - ANNEX1 
Name of programme or project  WHO, WIPO, WTO Workshop on Innovation and Access to diagnostics for COVID -19 and beyond  
Date and end date  28 October 2022 - 28 October 2022  
Beneficiary Member(s) or observer(s)  Afghanistan; Albania; Algeria; Andorra; Angola; Antigua and Barbuda; Argentina; Armenia; Australia; Austria; 
Azerbaijan; Bahamas;  Kingdom of Bahrain; Bangladesh; Barbados; Belarus; Belgium; Belize; Benin; Bhutan; 
Plurinational State of Bolivia; Bosnia and Herzegovina; Botswana; Brazil; Brunei Darussalam; Bulgaria; Burkina 
Faso; Burundi; Cabo Verde; Cambodia; Cameroon; Canada; Centra l African Republic; Chad; Chile; China; 
Colombia; Comoros; Congo; Costa Rica; Côte d 'Ivoire; Croatia; Cuba; Curaçao; Cyprus; Czech Republic; 
Democratic Republic of the Congo; Denmark; Djibouti; Dominica; Dominican Republic; Ecuador; Egypt; El 
Salvador; Equ atorial Guinea; Estonia; Eswatini; Ethiopia; European Union; Fiji; Finland; France; Gabon; The 
Gambia; Georgia; Germany; Ghana; Greece; Grenada; Guatemala; Guinea; Guinea -Bissau; Guyana; Haiti; 
Honduras; Hong Kong, China; Hungary; Iceland; India; Indonesia ; Iran; Iraq; Ireland; Israel; Italy; Jamaica; 
Japan; Jordan; Kazakhstan; Kenya; Republic of Korea; the State of Kuwait; Kyrgyz Republic; Lao People 's 
Democratic Republic; Latvia; Lebanese Republic; Lesotho; Liberia; Libya; Liechtenstein; Lithuania; 
Luxemb ourg; Macao, China; Madagascar; Malawi; Malaysia; Maldives; Mali; Malta; Mauritania; Mauritius; 
Mexico; Republic of Moldova; Mongolia; Montenegro; Morocco; Mozambique; Myanmar; Namibia; Nepal; 
Netherlands; New Zealand; Nicaragua; Niger; Nigeria; North Mace donia; Norway; Oman; Pakistan; Panama; 
Papua New Guinea; Paraguay; Peru; Philippines; Poland; Portugal; Qatar; Romania; Russian Federation; 
Rwanda; Saint Kitts and Nevis; Saint Lucia; Saint Vincent and the Grenadines; Samoa; Sao Tomé and Principe; 
Kingdom of Saudi Arabia; Senegal; Serbia; Seychelles; Sierra Leone; Singapore; Slovak Republic; Slovenia; 
Solomon Islands; Somalia; South Africa; South Sudan; Spain; Sri Lanka; Sudan; Suriname; Sweden; 
Switzerland; Syrian Arab Republic; The Separate Customs Territ ory of Taiwan, Penghu, Kinmen and Matsu; 
Tajikistan; Tanzania; Thailand; Timor -Leste; Togo; Tonga; Trinidad and Tobago; Tunisia; Türkiye; 
Turkmenistan; Uganda; Ukraine; United Arab Emirates; United Kingdom; United States of America; Uruguay; 
Uzbekistan; Va nuatu; Bolivarian Republic of Venezuela; Viet Nam; Yemen; Zambia; Zimbabwe  
Brief description  The workshop, held virtually, was focused on diagnostics – specifically, in vitro diagnostics – and there were 
discussions on challenges, opportunities and the way forward to secure innovation and access to diagnostics.  
Beneficiary institution or audienc e  
Technical cooperation provider(s)  WHO, WIPO, WTO  
Outputs or impact  The workshop was aimed at strengthening the capacity of policymakers and experts in member governments 
to assess medical devices and diagnostics therapeutic technologies in response to  COVID -19. 
 
1 In English only.   
  IP/C/R/TC/WHO/4  
 
- 8 - Name of programme or project  WHO, WIPO, WTO Workshop on Innovation and Access to diagnostics for COVID -19 and beyond  
Website for further information  https://www.who.int/news -room/events/detail/2022/10/28/default -calendar/who -wipo-wto-workshop ---
innovation -and-access -to-diagnostics -for-covid-19-and-
beyond#:~:text=The%20World%20Health%20Organization%20 (WHO,Geneva%20time)%20in%20virtual%2
0format  
Contact point for further information   
  
  IP/C/R/TC/WHO/4  
 
- 9 - Name of programme or project  WHO, WIPO and WTO Symposium on "COVID -19 Pandemic: Response, Preparedness, Resilience " 
Date and end date 16 December 2022 - 16 December 2022  
Beneficiary Member(s) or observer(s)  Afghanistan; Albania; Angola; Antigua and Barbuda; Argentina; Armenia; Australia; Austria; Kingdom of 
Bahrain; Bangladesh; Barbados; Belgium; Belize; Benin; Plurinational State of Bolivia; Botswana; Brazil; Brunei 
Darussalam; Bulgaria; Burkina Faso; Burund i; Cabo Verde; Cambodia; Cameroon; Canada; Central African 
Republic; Chad; Chile; China; Colombia; Congo; Costa Rica; Côte d 'Ivoire; Croatia; Cuba; Cyprus; Czech 
Republic; Democratic Republic of the Congo; Denmark; Djibouti; Dominica; Dominican Republic; E cuador; 
Egypt; El Salvador; Estonia; Eswatini; European Union; Fiji; Finland; France; Gabon; The Gambia; Georgia; 
Germany; Ghana; Greece; Grenada; Guatemala; Guinea; Guinea -Bissau; Guyana; Haiti; Honduras; Hong Kong, 
China; Hungary; Iceland; India; Indones ia; Ireland; Israel; Italy; Jamaica; Japan; Jordan; Kazakhstan; Kenya; 
Republic of Korea; the State of Kuwait; Kyrgyz Republic; Lao People 's Democratic Republic; Latvia; Lesotho; 
Liberia; Liechtenstein; Lithuania; Luxembourg; Macao, China; Madagascar; Mala wi; Malaysia; Maldives; Mali; 
Malta; Mauritania; Mauritius; Mexico; Republic of Moldova; Mongolia; Montenegro; Morocco; Mozambique; 
Myanmar; Namibia; Nepal; Netherlands; New Zealand; Nicaragua; Niger; Nigeria; North Macedonia; Norway; 
Oman; Pakistan; Panam a; Papua New Guinea; Paraguay; Peru; Philippines; Poland; Portugal; Qatar; Romania; 
Russian Federation; Rwanda; Saint Kitts and Nevis; Saint Lucia; Saint Vincent and the Grenadines; Samoa; 
Kingdom of Saudi Arabia; Senegal; Seychelles; Sierra Leone; Singapo re; Slovak Republic; Slovenia; Solomon 
Islands; South Africa; Spain; Sri Lanka; Suriname; Sweden; Switzerland; The Separate Customs Territory of 
Taiwan, Penghu, Kinmen and Matsu; Tajikistan; Tanzania; Thailand; Togo; Tonga; Trinidad and Tobago; 
Tunisia; Tü rkiye; Uganda; Ukraine; United Arab Emirates; United Kingdom; United States of America; Uruguay; 
Vanuatu; Bolivarian Republic of Venezuela; Viet Nam; Yemen; Zambia; Zimbabwe  
Brief description  The Symposium was the ninth in a series of joint technical symp osia convened by the three organizations. The 
objective of the Symposium was to examine key challenges of the COVID -19 pandemic experienced within the 
frameworks of health, trade and intellectual property (IP) and to discuss the way forward to build resili ence to 
be better prepared for future pandemics. This event was held in hybrid format at the WIPO headquarters.  
Beneficiary institution or audience   
Technical cooperation provider(s)  WHO, WIPO, WTO  
Outputs or impact   
Website for further information  https://www.wipo.int/meetings/en/details.jsp?meeting_id=72248  
Contact point for further information   
  
  IP/C/R/TC/WHO/4  
 
- 10 - Name of programme or project  WHO, WIPO, WTO Webinar on "Technology Transfer from the Perspectives of Practitioners " 
Date and end date  27 June 2023 - 27 June 2023  
Beneficiary Member(s) or observer(s)  Afghanistan; Albania; Algeria; Andorra; Angola; Antigua and Barbuda; Argentina; Armenia; Australia; Austria; 
Azerbaijan; Bahamas; Kingdom of Bahrain; Bangladesh; Barbados; Belarus; Belgium; Belize; Benin; Bhutan; 
Plurinational State of Bolivia; Bosnia and Herzegovina; Botswana; Brazil; Brunei Darussalam; Bulgaria; Burkina 
Faso; Burundi; Cabo Verde; Cambodia; Cameroon; Canada; Central African Republic; Chad; Chile; China; 
Colombia; Comoros; Congo; Costa Rica; Côte d 'Ivoire; Croatia; Cuba; Curaçao; Cyprus; Cz ech Republic; 
Democratic Republic of the Congo; Denmark; Djibouti; Dominica; Dominican Republic; Ecuador; Egypt; El 
Salvador; Equatorial Guinea; Estonia; Eswatini; Ethiopia; Fiji; Finland; France; Gabon; The Gambia; Georgia; 
Germany; Ghana; Greece; Grenada ; Guatemala; Guinea; Guinea -Bissau; Guyana; Haiti; Holy See; Honduras; 
Hong Kong, China; Hungary; Iceland; India; Indonesia; Iran; Iraq; Ireland; Israel; Italy; Jamaica; Japan; 
Jordan; Kazakhstan; Kenya; Republic of Korea; the State of Kuwait; Kyrgyz Repub lic; Lao People 's Democratic 
Republic; Latvia; Lebanese Republic; Lesotho; Liberia; Libya; Liechtenstein; Lithuania; Luxembourg; Macao, 
China; Madagascar; Malawi; Malaysia; Maldives; Mali; Malta; Mauritania; Mauritius; Mexico; Republic of 
Moldova; Mongolia ; Montenegro; Morocco; Mozambique; Myanmar; Namibia; Nepal; Netherlands; New 
Zealand; Nicaragua; Niger; Nigeria; North Macedonia; Norway; Oman; Pakistan; Panama; Papua New Guinea; 
Paraguay; Peru; Philippines; Poland; Portugal; Qatar; Romania; Russian Feder ation; Rwanda; Saint Kitts and 
Nevis; Saint Lucia; Saint Vincent and the Grenadines; Samoa; Sao Tomé and Principe; Kingdom of Saudi Arabia; 
Senegal; Serbia; Seychelles; Sierra Leone; Singapore; Slovak Republic; Slovenia; Solomon Islands; Somalia; 
South Afr ica; South Sudan; Spain; Sri Lanka; Sudan; Suriname; Sweden; Switzerland; Syrian Arab Republic; 
The Separate Customs Territory of Taiwan, Penghu, Kinmen and Matsu; Tajikistan; Tanzania; Thailand; Timor -
Leste; Togo; Tonga; Trinidad and Tobago; Tunisia; Türk iye; Turkmenistan; Uganda; Ukraine; United Arab 
Emirates; United Kingdom; United States of America; Uruguay; Uzbekistan; Vanuatu; Bolivarian Republic of 
Venezuela; Viet Nam; Yemen; Zambia; Zimbabwe  
Brief description  This practical capacity -building webina r was the fourth in the series of trilateral workshops and it drew from the 
experience and perspectives of technology transfer practitioners working on the ground.  
Beneficiary institution or audience   
Technical cooperation provider(s)  WHO, WIPO, WTO  
Outputs or impact  The purpose of the webinar was to strengthen the capacity of policymakers and experts to achieve equitable 
access to COVID -19 health technologies and to be better prepared for future pandemics.  
Website for further information  https://cdn.who.int/media/docs/default -source/essential -medicines/intel lectual -property/trilateral -webinar -
on-technology -transfer -programme -27june2023.pdf?sfvrsn=cec74276_1  
Contact point for further information   
  
  IP/C/R/TC/WHO/4  
 
- 11 - Name of programme or project  License by Medigen Vaccine Biologics Corp. under the auspices of WHO COVID -19 Technology 
Access Pool  
Date and end date  18 July 2023  
Beneficiary Member(s) or observer(s)  Afghanistan; Albania; Angola; Antigua and Barbuda; Argentina; Armenia; Australia; Austria; Kingdom of 
Bahrain; Bangladesh; Barba dos; Belgium; Belize; Benin; Plurinational State of Bolivia; Botswana; Brazil; Brunei 
Darussalam; Bulgaria; Burkina Faso; Burundi; Cabo Verde; Cambodia; Cameroon; Canada; Central African 
Republic; Chad; Chile; China; Colombia; Congo; Costa Rica; Côte d 'Ivoire; Croatia; Cuba; Cyprus; Czech 
Republic; Democratic Republic of the Congo; Denmark; Djibouti; Dominica; Dominican Republic; Ecuador; 
Egypt; El Salvador; Estonia; Eswatini; European Union; Fiji; Finland; France; Gabon; The Gambia; Georgia; 
Germany; Ghana ; Greece; Grenada; Guatemala; Guinea; Guinea -Bissau; Guyana; Haiti; Honduras; Hong Kong, 
China; Hungary; Iceland; India; Indonesia; Ireland; Israel; Italy; Jamaica; Japan; Jordan; Kazakhstan; Kenya; 
Republic of Korea; the State of Kuwait; Kyrgyz Republic; Lao People 's Democratic Republic; Latvia; Lesotho; 
Liberia; Liechtenstein; Lithuania; Luxembourg; Macao, China; Madagascar; Malawi; Malaysia; Maldives; Mali; 
Malta; Mauritania; Mauritius; Mexico; Republic of Moldova; Mongolia; Montenegro; Morocco; Mozambiq ue; 
Myanmar; Namibia; Nepal; Netherlands; New Zealand; Nicaragua; Niger; Nigeria; North Macedonia; Norway; 
Oman; Pakistan; Panama; Papua New Guinea; Paraguay; Peru; Philippines; Poland; Portugal; Qatar; Romania; 
Russian Federation; Rwanda; Saint Kitts and Nevis; Saint Lucia; Saint Vincent and the Grenadines; Samoa; 
Kingdom of Saudi Arabia; Senegal; Seychelles; Sierra Leone; Singapore; Slovak Republic; Slovenia; Solomon 
Islands; South Africa; Spain; Sri Lanka; Suriname; Sweden; Switzerland; The Separate Cust oms Territory of 
Taiwan, Penghu, Kinmen and Matsu; Tajikistan; Tanzania; Thailand; Togo; Tonga; Trinidad and Tobago; 
Tunisia; Türkiye; Uganda; Ukraine; United Arab Emirates; United Kingdom; United States of America; Uruguay; 
Vanuatu; Bolivarian Republic of  Venezuela; Viet Nam; Yemen; Zambia; Zimbabwe  
Brief description  Under the auspices of C -TAP, the Medicines Patent Pool signed a worldwide license with Medigen Vaccine 
Biologics Corp. for a COVID -19 vaccine based on the COVID -19 spike protein sequence that it licensed from the 
US National Institutes of Health (NIH).  
Beneficiary institution or audience  Medicines Patent Pool, manufacturers of COVID -19 health products  
Technical cooperation provider(s)  WHO 
Outputs or impact  This is the first transparent, global, non -exclusive license for a COVID -19 vaccine and the first health technology 
developed by a private company and included in C -TAP. 
Website for further information  https://www.who.int/initiatives/covid -19-technology -access -pool/medigen -license -to-c-tap 
Contact point for further information   
  
  IP/C/R/TC/WHO/4  
 
- 12 - Name of programme or project  License by the Spanish National Research Council (CSIC) under the auspices of WHO COVID -19 
Technology Access Pool  
Date and end date  18 July 2023  
Beneficiary Member(s) or observer(s)  Afghanistan; Albania; Algeria; Andorra; Angola; Antigua and Barbuda; Argentina; Armenia; Australia; Austria; 
Azerbaijan; Bahamas; Kingdom of Bahrain; Bangladesh; Barbados; Belarus; Belgium; Belize; Benin; Bhutan; 
Plurinational State of Bolivia; Bosnia and Herzegovina; Botswana; Brazil; Brunei Darussalam; Bulgaria; Burkina 
Faso; Burundi; Cabo Verde; Cambodia; Cameroon; Canada; Central African Republic; Chad; Chile; China; 
Colombia; Comoros; Congo; Costa Rica; Côte d 'Ivoire; Croatia; Cuba; Curaçao; Cyprus; Cz ech Republic; 
Democratic Republic of the Congo; Denmark; Djibouti; Dominica; Dominican Republic; Ecuador; Egypt; El 
Salvador; Equatorial Guinea; Estonia; Eswatini; Ethiopia; European Union; Fiji; Finland; France; Gabon; The 
Gambia; Georgia; Germany; Ghana;  Greece; Grenada; Guatemala; Guinea; Guinea -Bissau; Guyana; Haiti; Holy 
See; Honduras; Hong Kong, China; Hungary; Iceland; India; Indonesia; Iran; Iraq; Ireland; Israel; Italy; 
Jamaica; Japan; Jordan; Kazakhstan; Kenya; Republic of Korea; the State of Kuwa it; Kyrgyz Republic; Lao 
People 's Democratic Republic; Latvia; Lebanese Republic; Lesotho; Liberia; Libya; Liechtenstein; Lithuania; 
Luxembourg; Macao, China; Madagascar; Malawi; Malaysia; Maldives; Mali; Malta; Mauritania; Mauritius; 
Mexico; Republic of M oldova; Mongolia; Montenegro; Morocco; Mozambique; Myanmar; Namibia; Nepal; 
Netherlands; New Zealand; Nicaragua; Niger; Nigeria; North Macedonia; Norway; Oman; Pakistan; Panama; 
Papua New Guinea; Paraguay; Peru; Philippines; Poland; Portugal; Qatar; Romani a; Russian Federation; 
Rwanda; Saint Kitts and Nevis; Saint Lucia; Saint Vincent and the Grenadines; Samoa; Sao Tomé and Principe; 
Kingdom of Saudi Arabia; Senegal; Serbia; Seychelles; Sierra Leone; Singapore; Slovak Republic; Slovenia; 
Solomon Islands; So malia; South Africa; South Sudan; Spain; Sri Lanka; Sudan; Suriname; Sweden; 
Switzerland; Syrian Arab Republic; The Separate Customs Territory of Taiwan, Penghu, Kinmen and Matsu; 
Tajikistan; Tanzania; Thailand; Timor -Leste; Togo; Tonga; Trinidad and Tobag o; Tunisia; Türkiye; 
Turkmenistan; Uganda; Ukraine; United Arab Emirates; United Kingdom; United States of America; Uruguay; 
Uzbekistan; Vanuatu; Bolivarian Republic of Venezuela; Viet Nam; Yemen; Zambia; Zimbabwe  
Brief description  Under the auspices of C -TAP, the Medicines Patent Pool signed a worldwide license with the Spanish National 
Research Council (CSIC) for a COVID -19 vaccine consisting of a Modified Vaccinia Virus Ankara (MVA) vector 
expressing a full -length prefusion -stabil ized SARS -CoV-2 spike protein and called MVA -CoV2-S(3P).   
Beneficiary institution or audience  Medicines Patent Pool, manufacturers of COVID -19 health products  
Technical cooperation provider(s)  WHO 
Outputs or impact  This is the second technology developed by CSIC and included in C -TAP. 
Website for further information  https://www.who.int/initiatives/covid -19-technology -access -pool/csic -license -to-c-tap 
Contact point for further information   
  
  IP/C/R/TC/WHO/4  
 
- 13 - Name of programme or project  License by University of Chile under the auspices of the WHO COVID -19 Technology Access Pool  
Date and end date  18 July 2023  
Beneficiary Member(s) or observer(s)  Afghanistan; Albania; Algeria; Andorra; Angola; Antigua and Barbuda; Argentina; Armenia; Australia; Austria; 
Azerbaijan; Bahamas; Kingdom of Bahrain; Bangladesh; Barbados; Belarus; Belgium; Belize; Benin; Bhutan; 
Plurinational State of Bolivia; Bosnia and Herzegovina; Botswana; Brazil; Brunei Darussalam; Bulgaria; Burkina 
Faso; Burundi; Cabo Verde; Cambodia; Cameroon; Canada; Central African Republic; Chad; Chile; China; 
Colombia; Comoros; Congo; Costa Rica; Côte d 'Ivoire; Croatia; Cuba; Curaçao; Cyprus; Cz ech Republic; 
Democratic Republic of the Congo; Denmark; Djibouti; Dominica; Dominican Republic; Ecuador; Egypt; El 
Salvador; Equatorial Guinea; Estonia; Eswatini; Ethiopia; European Union; Fiji; Finland; France; Gabon; The 
Gambia; Georgia; Germany; Ghana;  Greece; Grenada; Guatemala; Guinea; Guinea -Bissau; Guyana; Haiti; Holy 
See; Honduras; Hong Kong, China; Hungary; Iceland; India; Indonesia; Iran; Iraq; Ireland; Israel; Italy; 
Jamaica; Japan; Jordan; Kazakhstan; Kenya; Republic of Korea; the State of Kuwa it; Kyrgyz Republic; Lao 
People 's Democratic Republic; Latvia; Lebanese Republic; Lesotho; Liberia; Libya; Liechtenstein; Lithuania; 
Luxembourg; Macao, China; Madagascar; Malawi; Malaysia; Maldives; Mali; Malta; Mauritania; Mauritius; 
Mexico; Republic of M oldova; Mongolia; Montenegro; Morocco; Mozambique; Myanmar; Namibia; Nepal; 
Netherlands; New Zealand; Nicaragua; Niger; Nigeria; North Macedonia; Norway; Oman; Pakistan; Panama; 
Papua New Guinea; Paraguay; Peru; Philippines; Poland; Portugal; Qatar; Romani a; Russian Federation; 
Rwanda; Saint Kitts and Nevis; Saint Lucia; Saint Vincent and the Grenadines; Samoa; Sao Tomé and Principe; 
Kingdom of Saudi Arabia; Senegal; Serbia; Seychelles; Sierra Leone; Singapore; Slovak Republic; Slovenia; 
Solomon Islands; So malia; South Africa; South Sudan; Spain; Sri Lanka; Sudan; Suriname; Sweden; 
Switzerland; Syrian Arab Republic; The Separate Customs Territory of Taiwan, Penghu, Kinmen and Matsu; 
Tajikistan; Tanzania; Thailand; Timor -Leste; Togo; Tonga; Trinidad and Tobag o; Tunisia; Türkiye; 
Turkmenistan; Uganda; Ukraine; United Arab Emirates; United Kingdom; United States of America; Uruguay; 
Uzbekistan; Vanuatu; Bolivarian Republic of Venezuela; Viet Nam; Yemen; Zambia; Zimbabwe  
Brief description  Under the auspices of C -TAP, the Medicines Patent Pool signed a worldwide license with the University of Chile 
for a system for quantification of neutralizing antibodies (NAbs) against SARS -CoV-2. 
Beneficiary institution or audience  Medicines Patent Pool, manufactu rers of COVID -19 health products  
Technical cooperation provider(s)  WHO 
Outputs or impact  The agreement covers transfer of all know -how, protocols and biological materials needed to manufacture the 
diagnostic test.  
Website for further information  https://www.who.int/initiatives/covid -19-technology -access -pool/university -of-chile-license -to-c-tap 
Contact point for further information   
  
  IP/C/R/TC/WHO/4  
 
- 14 - Name of programme or project  WHO Technology Access Pool Database  
Date and end date  29 August 2023  
Beneficiary Member(s) or observer(s)  Afghanistan; Albania; Algeria; Andorra; Angola; Antigua and Barbuda; Argentina; Armenia; Australia; Austria; 
Azerbaijan; Bahamas; Kingdom of Bahrain; Bangladesh; Barbados; Belarus; Belgium; Belize; Benin; Bhutan; 
Plurinational State of Bolivia; Bosnia and Herzegovina; Botswana; Brazil; Brunei Darussalam; Bulgaria; Burkina 
Faso; Burundi; Cabo Verde; Cambodia; Cameroon; Canada; Central African Republic; Chad; Chile; China; 
Colombia; Comoros; Congo; Costa Rica; Côte d 'Ivoire; Croatia; Cuba; Curaçao; Cyprus; Cz ech Republic; 
Democratic Republic of the Congo; Denmark; Djibouti; Dominica; Dominican Republic; Ecuador; Egypt; El 
Salvador; Equatorial Guinea; Estonia; Eswatini; Ethiopia; European Union; Fiji; Finland; France; Gabon; The 
Gambia; Georgia; Germany; Ghana;  Greece; Grenada; Guatemala; Guinea; Guinea -Bissau; Guyana; Haiti; Holy 
See; Honduras; Hong Kong, China; Hungary; Iceland; India; Indonesia; Iran; Iraq; Ireland; Israel; Italy; 
Jamaica; Japan; Jordan; Kazakhstan; Kenya; Republic of Korea; the State of Kuwa it; Kyrgyz Republic; Lao 
People 's Democratic Republic; Latvia; Lebanese Republic; Lesotho; Liberia; Libya; Liechtenstein; Lithuania; 
Luxembourg; Macao, China; Madagascar; Malawi; Malaysia; Maldives; Mali; Malta; Mauritania; Mauritius; 
Mexico; Republic of M oldova; Mongolia; Montenegro; Morocco; Mozambique; Myanmar; Namibia; Nepal; 
Netherlands; New Zealand; Nicaragua; Niger; Nigeria; North Macedonia; Norway; Oman; Pakistan; Panama; 
Papua New Guinea; Paraguay; Peru; Philippines; Poland; Portugal; Qatar; Romani a; Russian Federation; 
Rwanda; Saint Kitts and Nevis; Saint Lucia; Saint Vincent and the Grenadines; Samoa; Sao Tomé and Principe; 
Kingdom of Saudi Arabia; Senegal; Serbia; Seychelles; Sierra Leone; Singapore; Slovak Republic; Slovenia; 
Solomon Islands; So malia; South Africa; South Sudan; Spain; Sri Lanka; Sudan; Suriname; Sweden; 
Switzerland; Syrian Arab Republic; The Separate Customs Territory of Taiwan, Penghu, Kinmen and Matsu; 
Tajikistan; Tanzania; Thailand; Timor -Leste; Togo; Tonga; Trinidad and Tobag o; Tunisia; Türkiye; 
Turkmenistan; Uganda; Ukraine; United Arab Emirates; United Kingdom; United States of America; Uruguay; 
Uzbekistan; Vanuatu; Bolivarian Republic of Venezuela; Viet Nam; Yemen; Zambia; Zimbabwe  
Brief description  The WHO Technology Acce ss Pool Database provides wide -ranging information on selected therapeutics, 
diagnostics, vaccines and other health products to tackle COVID -19 and other endemic diseases. This publicly 
available database includes information on clinical trials, patents an d licensing, manufacturers, and regulatory 
status of key health products for informed decision -making.  
Beneficiary institution or audience  WHO member States, procurement agencies, manufacturers of health products, academics, and other public 
health actors  
Technical cooperation provider(s)  WHO 
Outputs or impact  The database will support efforts for sharing of intellectual property, knowledge and data through public health -
driven voluntary, non -exclusive and transparent licenses.  
Website for further information  https://tap -database.who.int   
Contact point for further information   
  
  IP/C/R/TC/WHO/4  
 
- 15 - Name of programme or project  Study on "Strategies to facilitate sharing of technology and knowledge ". 
Date and end date  3 October 2023  
Beneficiary Member(s) or observer(s)  Afghanistan; Albania; Algeria; Andorra; Angola; Antigua and Barbuda; Argentina; Armenia; Australia; Austria; 
Azerbaijan; Bahamas; Kingdom of Bahrain; Bangladesh; Barbados; Belarus; Belgium; Belize; Benin; Bhutan; 
Plurinational State of Bolivia; Bosnia and Herzegovina; Botswana; Brazil; Brunei Darussalam; Bulgaria; Burkina 
Faso; Burundi; Cabo Verde; Cambodia; Cameroon; Canada; Central African Republic; Chad; Chile; China; 
Colombia; Comoros; Congo; Costa Rica; Côte d 'Ivoire; Croatia; Cuba; Curaçao; Cyprus; Cz ech Republic; 
Democratic Republic of the Congo; Denmark; Djibouti; Dominica; Dominican Republic; Ecuador; Egypt; El 
Salvador; Equatorial Guinea; Estonia; Eswatini; Ethiopia; European Union; Fiji; Finland; France; Gabon; The 
Gambia; Georgia; Germany; Ghana;  Greece; Grenada; Guatemala; Guinea; Guinea -Bissau; Guyana; Haiti; Holy 
See; Honduras; Hong Kong, China; Hungary; Iceland; India; Indonesia; Iran; Iraq; Ireland; Israel; Italy; 
Jamaica; Japan; Jordan; Kazakhstan; Kenya; Republic of Korea; the State of Kuwa it; Kyrgyz Republic; Lao 
People 's Democratic Republic; Latvia; Lebanese Republic; Lesotho; Liberia; Libya; Liechtenstein; Lithuania; 
Luxembourg; Macao, China; Madagascar; Malawi; Malaysia; Maldives; Mali; Malta; Mauritania; Mauritius; 
Mexico; Republic of M oldova; Mongolia; Montenegro; Morocco; Mozambique; Myanmar; Namibia; Nepal; 
Netherlands; New Zealand; Nicaragua; Niger; Nigeria; North Macedonia; Norway; Oman; Pakistan; Panama; 
Papua New Guinea; Paraguay; Peru; Philippines; Poland; Portugal; Qatar; Romani a; Russian Federation; 
Rwanda; Saint Kitts and Nevis; Saint Lucia; Saint Vincent and the Grenadines; Samoa; Sao Tomé and Principe; 
Kingdom of Saudi Arabia; Senegal; Serbia; Seychelles; Sierra Leone; Singapore; Slovak Republic; Slovenia; 
Solomon Islands; So malia; South Africa; South Sudan; Spain; Sri Lanka; Sudan; Suriname; Sweden; 
Switzerland; Syrian Arab Republic; The Separate Customs Territory of Taiwan, Penghu, Kinmen and Matsu; 
Tajikistan; Tanzania; Thailand; Timor -Leste; Togo; Tonga; Trinidad and Tobag o; Tunisia; Türkiye; 
Turkmenistan; Uganda; Ukraine; United Arab Emirates; United Kingdom; United States of America; Uruguay; 
Uzbekistan; Vanuatu; Bolivarian Republic of Venezuela; Viet Nam; Yemen; Zambia; Zimbabwe  
Brief description  The WHO secretariat adm inistered a questionnaire for member States to identify legislation, regulations, 
guidelines and procedures that can be amended or introduced to encourage sharing of health technologies. The 
study summarizes responses from member States and analyzes possible measures that may be implemented 
at the country level to encourage participation of technology holders in C -TAP.  
Beneficiary institution or audience   
Technical cooperation provider(s)  WHO 
Outputs or impact  This study is aimed at promoting engagement of technology holders with C -TAP to share essential health 
technologies for global equitable access. The discussion contained in the study is intended to inform all actors 
involved in the process of introducing or ame nding legislations, regulations, guidelines, and procedures to 
implement incentives for voluntary transfer of critical health technologies to reduce the dire effects of health 
emergencies globally.  
Website for further information  https://www.who.int/southeastasia/publications/i/item/9789240073951   
Contact point for further information   
  
  IP/C/R/TC/WHO/4  
 
- 16 - Name of programme or project  Briefing Document on "Improving access to novel COVID -19 treatments " 
Date and end date  11 April 2023  
Beneficiary Member(s) or observer(s)  Afghanistan; Albania; Algeria; Andorra; Angola; Antigua and Barbuda; Argentina; Armenia; Australia; Austria; 
Azerbaijan; Bahamas; Kingdom of Bahrain; Bangladesh; Barbados; Belarus; Belgium; Belize; Benin; Bhutan; 
Plurinational State of Bolivia; Bosnia and Herzegovina; Botswana; Brazil; Brunei Darussalam; Bulgaria; Burkina 
Faso; Burundi; Cabo Verde; Cambodia; Cameroon; Canada; Central African Republic; Chad; Chile; China; 
Colombia; Comoros; Congo; Costa Rica; Côte d 'Ivoire; Croatia; Cuba; Curaçao; Cyprus; Cz ech Republic; 
Democratic Republic of the Congo; Denmark; Djibouti; Dominica; Dominican Republic; Ecuador; Egypt; El 
Salvador; Equatorial Guinea; Estonia; Eswatini; Ethiopia; European Union; Fiji; Finland; France; Gabon; The 
Gambia; Georgia; Germany; Ghana;  Greece; Grenada; Guatemala; Guinea; Guinea -Bissau; Guyana; Haiti; Holy 
See; Honduras; Hong Kong, China; Hungary; Iceland; India; Indonesia; Iran; Iraq; Ireland; Israel; Italy; 
Jamaica; Japan; Jordan; Kazakhstan; Kenya; Republic of Korea; the State of Kuwa it; Kyrgyz Republic; Lao 
People 's Democratic Republic; Latvia; Lebanese Republic; Lesotho; Liberia; Libya; Liechtenstein; Lithuania; 
Luxembourg; Macao, China; Madagascar; Malawi; Malaysia; Maldives; Mali; Malta; Mauritania; Mauritius; 
Mexico; Republic of M oldova; Mongolia; Montenegro; Morocco; Mozambique; Myanmar; Namibia; Nepal; 
Netherlands; New Zealand; Nicaragua; Niger; Nigeria; North Macedonia; Norway; Oman; Pakistan; Panama; 
Papua New Guinea; Paraguay; Peru; Philippines; Poland; Portugal; Qatar; Romani a; Russian Federation; 
Rwanda; Saint Kitts and Nevis; Saint Lucia; Saint Vincent and the Grenadines; Samoa; Sao Tomé and Principe; 
Kingdom of Saudi Arabia; Senegal; Serbia; Seychelles; Sierra Leone; Singapore; Slovak Republic; Slovenia; 
Solomon Islands; So malia; South Africa; South Sudan; Spain; Sri Lanka; Sudan; Suriname; Sweden; 
Switzerland; Syrian Arab Republic; The Separate Customs Territory of Taiwan, Penghu, Kinmen and Matsu; 
Tajikistan; Tanzania; Thailand; Timor -Leste; Togo; Tonga; Trinidad and Tobag o; Tunisia; Türkiye; 
Turkmenistan; Uganda; Ukraine; United Arab Emirates; United Kingdom; United States of America; Uruguay; 
Uzbekistan; Vanuatu; Bolivarian Republic of Venezuela; Viet Nam; Yemen; Zambia; Zimbabwe  
Brief description  The document explains s ome of the legal instruments that WHO member States can use to promote public 
health and access to COVID 19 therapeutics in the framework of their multilateral trade obligations and rights, 
and according to their national legislation and level of developme nt. 
Beneficiary institution or audience  WHO member States  
Technical cooperation provider(s)  WHO, Unitaid  
Outputs or impact  It is intended to support countries dealing with challenges at the intersection of public health and intellectual 
property, to inc rease access to novel COVID -19 therapeutics and to facilitate alternative and more affordable 
sourcing of such treatments, where possible.  
Website for further information  https://www.who.int/publications/m/item/improving -accessto -novel -covid-19treatments  
Contact point for further information   
  
  IP/C/R/TC/WHO/4  
 
- 17 - Name of programme or project  Establishment of a global training hub in biomanufacturing  
Date and end date  26 May 2023  
Beneficiary Member(s) or observer(s)  Afghanistan; Albania; Algeria; Andorra; Angola; Antigua and Barbuda; Argentina; Armenia; Australia; Austria; 
Azerbaijan; Bahamas; Kingdom of Bahrain; Bangladesh; Barbados; Belarus; Belgium; Belize; Benin; Bhutan; 
Plurinational State of Bolivia; Bosnia and Herzegovina; Botswana; Brazil; Brunei Darussalam; Bulgaria; Burkina 
Faso; Burundi; Cabo Verde; Cambodia; Cameroon; Canada; Central African Republic; Chad; Chile; China; 
Colombia; Comoros; Congo; Costa Rica; Côte d 'Ivoire; Croatia; Cuba; Curaçao; Cyprus; Cz ech Republic; 
Democratic Republic of the Congo; Denmark; Djibouti; Dominica; Dominican Republic; Ecuador; Egypt; El 
Salvador; Equatorial Guinea; Estonia; Eswatini; Ethiopia; European Union; Fiji; Finland; France; Gabon; The 
Gambia; Georgia; Germany; Ghana;  Greece; Grenada; Guatemala; Guinea; Guinea -Bissau; Guyana; Haiti; Holy 
See; Honduras; Hong Kong, China; Hungary; Iceland; India; Indonesia; Iran; Iraq; Ireland; Israel; Italy; 
Jamaica; Japan; Jordan; Kazakhstan; Kenya; Republic of Korea; the State of Kuwa it; Kyrgyz Republic; Lao 
People 's Democratic Republic; Latvia; Lebanese Republic; Lesotho; Liberia; Libya; Liechtenstein; Lithuania; 
Luxembourg; Macao, China; Madagascar; Malawi; Malaysia; Maldives; Mali; Malta; Mauritania; Mauritius; 
Mexico; Republic of M oldova; Mongolia; Montenegro; Morocco; Mozambique; Myanmar; Namibia; Nepal; 
Netherlands; New Zealand; Nicaragua; Niger; Nigeria; North Macedonia; Norway; Oman; Pakistan; Panama; 
Papua New Guinea; Paraguay; Peru; Philippines; Poland; Portugal; Qatar; Romani a; Russian Federation; 
Rwanda; Saint Kitts and Nevis; Saint Lucia; Saint Vincent and the Grenadines; Samoa; Sao Tomé and Principe; 
Kingdom of Saudi Arabia; Senegal; Serbia; Seychelles; Sierra Leone; Singapore; Slovak Republic; Slovenia; 
Solomon Islands; So malia; South Africa; South Sudan; Spain; Sri Lanka; Sudan; Suriname; Sweden; 
Switzerland; Syrian Arab Republic; The Separate Customs Territory of Taiwan, Penghu, Kinmen and Matsu; 
Tajikistan; Tanzania; Thailand; Timor -Leste; Togo; Tonga; Trinidad and Tobag o; Tunisia; Türkiye; 
Turkmenistan; Uganda; Ukraine; United Arab Emirates; United Kingdom; United States of America; Uruguay; 
Uzbekistan; Vanuatu; Bolivarian Republic of Venezuela; Viet Nam; Yemen; Zambia; Zimbabwe  
Brief description  In May 2023, WHO and th e Republic of Korea signed a Memorandum of Understanding to establish a global 
training hub in biomanufacturing. This global training centre will serve all low - and middle -income countries 
(LMICs) to produce biologicals, such as vaccines, insulin, monoclon al antibodies, and cancer medicines.  
Beneficiary institution or audience  WHO member States  
Technical cooperation provider(s)  WHO 
Outputs or impact  This initiative will contribute to building a skilled workforce with unique competencies required in bioproduction. 
The global bio -manufacturing training hub will complement the trainings delivered by the mRNA vaccine 
technology transfer hub in South Afric a.  
Website for further information  https://www.who.int /news/item/26 -05-2023-WHO-and-Republic -of-Korea -sign-landmark -agreement -to-boost -
biomanufacturing -
capacity#:~:text=WHO%20and%20the%20Republic%20of,monoclonal%20antibodies%2C%20and%20cancer%20medicines  
Contact point for f urther information   
 
 
__________  